Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2787)	7/26/2010 10:29:16 AM
From: Jibacoa	Respond to of 3722

ONXX is now up 16.23% on volume > 2x its ADV bigcharts.marketwatch.com It announced positive results from the PIIb 003-A1 of carfilzomib, a selective proteasome inhibitor, in patients with relapsed and refractory MM Carfilzomib was well-tolerated and there were no new or unexpected toxicities observed. Full results will be presented at an upcoming scientific meeting. Based on these results, ONXX is discussing with the FDA regarding next steps to file an NDA, which ONXX expects to submit by year-end. The ACTAY is $34.80 The stock has some resistant ahead, but could get there with further good news.<g> bigcharts.marketwatch.com Bernard